In contrast, as mentioned above, the inclusion of both of these facets of AD in mouse models is challenging; most models carrying multiple transgenes to achieve robust amyloid phenotypes rarely demonstrate significant tau pathology or neuronal loss. The gene discussed is MAPT; the disease is amyloidosis.